백신 보조제 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 투여 방법별, 용도별, 지역별, 부문별 예측(2025-2030년)

Vaccine Adjuvants Market Growth & Trends:

The global vaccine adjuvants market is expected to reach USD 4.86 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to grow at a CAGR of 4.32% from 2025 to 2030. The significance of adjuvant research in the development of vaccines has increased gradually due to inadequate immunogenicity of innovative vaccine antigens. In addition, the growing focus on long-lasting immunization effect against existing and emerging diseases is expected to boost the demand for vaccine adjuvants.

Furthermore, rising prevalence of cervical cancer is anticipated to boost the market. According to NCBI, around 15,000 females die every year due to cervical cancer. There are certain companies developing vaccine adjuvants for this type of cancer in order to enhance the efficacy, such as AS04 adjuvant-adsorbed (human papillomavirus vaccine) by GSK, which boosts the immune response for a longer duration.

Vaccine Adjuvants Market Report Highlights:

• The vaccine adjuvants market is segmented based on type into an adjuvant emulsion, pathogen, particulate, combination, and others. The particulate segment held the largest market share in 2024
• The infectious diseases segment accounted for the largest revenue share of 68.0% in 2024. This large share can be attributed to the gradually growing prevalence of infectious diseases, such as malaria, influenza, hepatitis A, B, & C, and others.
• The administration segment is categorized into oral, intradermal, intranasal, intramuscular, and others. Due to better immune specificity, the intramuscular segment accounted for the largest revenue share of 33.8% in 2024
• North America dominated the market and accounted for the largest revenue share of 39.4% in 2024. The factors contributing to the growth of the market in the North American region are a rise in investments for R&D of new therapeutics and an increase in fatal epidemic diseases.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Application
  • 1.1.3. Administration type
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Application outlook
  • 2.2.3. Administration outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Vaccine Adjuvants Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
  • 3.3.2. Market restraint analysis
• 3.4. Vaccine Adjuvants Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. Vaccine Adjuvants: Type Estimates & Trend Analysis

• 4.1. Vaccine Adjuvants Market: Key Takeaways
• 4.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2024 & 2030
• 4.3. Pathogen
  • 4.3.1. Pathogen market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Adjuvant emulsion
  • 4.4.1. Adjuvant emulsion market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Particulate
  • 4.5.1. Particulate market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Combination
  • 4.6.1. Combination market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Vaccine Adjuvants: Application Estimates & Trend Analysis

• 5.1. Vaccine Adjuvants Market: Key Takeaways
• 5.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2024 & 2030
• 5.3. Infectious diseases
  • 5.3.1. Infectious diseases market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Cancer
  • 5.4.1. Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Others
  • 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Vaccine Adjuvants: Administration Estimates & Trend Analysis

• 6.1. Vaccine Adjuvants Market: Key Takeaways
• 6.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2024 & 2030
• 6.3. Oral
  • 6.3.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.4. Intradermal
  • 6.4.1. Intradermal market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Intranasal
  • 6.5.1. Intranasal market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Intramuscular
  • 6.6.1. Intramuscular market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Vaccine Adjuvants Market: Regional Estimates & Trend Analysis

• 7.1. Regional Outlook
• 7.2. Vaccine Adjuvants Market by Region: Key Takeaways
• 7.3. North America
  • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.3. France
    • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.6. Denmark
    • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.8. Norway
    • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.2. China
    • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.3. India
    • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.5. Thailand
    • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Market Participant Categorization
  • 8.2.1. GSK
    • 8.2.1.1. Company overview
    • 8.2.1.2. Financial performance
    • 8.2.1.3. Product benchmarking
    • 8.2.1.4. Strategic initiatives
  • 8.2.2. Novartis/CSL
    • 8.2.2.1. Company overview
    • 8.2.2.2. Financial performance
    • 8.2.2.3. Product benchmarking
    • 8.2.2.4. Strategic initiatives
  • 8.2.3. Agenus
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. Adjuvance
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Novavax
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. SPI Pharma
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. Invivogen
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. Avanti Polar Lipids
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. Brentagg
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product benchmarking
    • 8.2.9.4. Strategic initiatives